Peter K. Kaiser, MD

KOLOA, Hawaii — In this Healio Video Perspective from Retina 2025, Peter K. Kaiser, MD, of Ocular Therapeutix, discusses positive data for OTX-TKI, a tyrosine kinase inhibitor designed to block VEGFR-1, VEGFR-2 and VEGFR-3.

CHICAGO — In this Healio Video Perspective from Eyecelerator@AAO, Peter K. Kaiser, MD, of Ocular Therapeutix, discusses the company’s shift to a retina-focused program.

In this video, Peter K. Kaiser, MD, founding director of the Digital Eye Optical Coherence Tomography Reading Center at the Cole Eye Institute, discusses the use of gene therapy in age-related macular degeneration.

In this video, Peter K. Kaiser, MD, founding director of the Digital Eye Optical Coherence Tomography Reading Center at the Cole Eye Institute, discusses the prevalence of age-related macular degeneration, risk factors for AMD and progression of the disease.

In this video, Peter K. Kaiser, MD, founding director of the Digital Eye Optical Coherence Tomography Reading Center at the Cole Eye Institute, discusses the "massive treatment burden" of the available therapies for age-related macular degeneration.

CHICAGO — In this video from Eyecelerator@AAO, Peter Kaiser, MD, discusses data from a phase 1 clinical study investigating OTX-TKI for the treatment of wet age-related macular degeneration.

Angiogenesis required the coordinated function of regulatory and effector proteins, including the VEGF, TIE, angiopoietin and integrin families, Peter K. Kaiser, MD, of the Cole Eye Institute at Cleveland Clinic, said in a video interview.

In this video from the virtual American Society of Retina Specialists meeting, Peter K. Kaiser, MD, discusses AXT107, a synthetic peptide designed to treat wet age-related macular degeneration and macular edema.

CHICAGO — At the American Society of Retina Specialists meeting, Peter K. Kaiser, MD, of the Cole Eye Institute at the Cleveland Clinic, discusses phase 2 study results of risuteganib (Luminate, Allegro Ophthalmics), for the treatment of intermediate, dry AMD with some vision loss. The treatment met the study’s primary outcome at 28 weeks with 8 letters of visual acuity gained.

WAIKOLOA, Hawaii — At Retina 2019 here, Peter K. Kaiser, MD, discusses the latest treatments in development and their mechanisms of action for treating patients with diabetic macular edema.